Article Text

Download PDFPDF
Intravenous/Intraperitoneal Paclitaxel and Intraperitoneal Carboplatin in Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Carcinoma: A Feasibility Study
  1. Shoji Nagao, MD, PhD*,
  2. Norihiro Iwasa, MD*,
  3. Akira Kurosaki, MD*,
  4. Tadaaki Nishikawa, MD*,
  5. Rie Ohishi, MD*,
  6. Kosei Hasegawa, MD, PhD*,
  7. Tomoko Goto, MD, PhD and
  8. Keiichi Fujiwara, MD, PhD*
  1. * Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Hidaka-city; and
  2. Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa-city, Saitama, Japan.
  1. Address correspondence and reprint requests to Shoji Nagao, MD, PhD, Department of Gynecologic Oncology, Saitama Medical University International Medical Center, 1397-1 Yamane, Hidaka-City 350-1241, Japan. E-mail: s_nagao{at}


Objective This study aimed to evaluate intravenous (IV)/intraperitoneal (IP) paclitaxel and IP carboplatin (TCipTip therapy) feasibility in epithelial ovarian (EOC), fallopian tube (FTC), or peritoneal carcinoma (PC) patients.

Methods From December 2007 to August 2010, 20 women with histologically confirmed stage IC to IV EOC, FTC, or PC received 6 TCipTip cycles after the primary cytoreductive surgery. Intravenous paclitaxel was administered at 135 mg/m2 followed by IP carboplatin based on the area under the curve = 6 on day 1; IP paclitaxel at 60 mg/m2 was administered on day 8. The toxicity grade was determined by CTCAE version 3.0. The institutional review board requested we reduce the IP paclitaxel dose in the first cycle to ensure safety.

Results Twenty women, including 18 with EOC, 1 with stage IIC FTC, and 1 with stage IV primary PC, received TCipTip therapy. There were 12 serous, 5 endometrioid, 1 mucinous, 1 clear cell adenocarcinoma, and 1 mixed carcinoma (clear cell and endometrioid) cases. Eleven women achieved optimal status at primary surgery. Grade 3/4 hematologic toxicity incidence was 73% (neutrocytopenia), 9% (thrombocytopenia), and 24% (anemia). Grade 3/4 nonhematologic toxicities were observed in 5 patients (4 with grade 3 allergy and 1 with grade 3 ileus). Twelve patients (60%) completed more than 6 chemotherapy cycles. Reasons for interruption included paclitaxel allergy, grade 2 abdominal pain, carboplatin allergy during the seventh cycle, disease progression, pleural embolism, ileus, and address change.

Conclusions Toxicities for TCipTip therapy were acceptable; this therapy is feasible for EOC, FTC, or PC patients. Further TCipTip therapy evaluation is warranted.

  • Epithelial ovarian carcinoma
  • Intraperitoneal carboplatin
  • Intraperitoneal paclitaxel

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.